dpp-4 inhibitors vs. glp-1 agonist dpp-4_inhibitors [TUSOM Comparison of GLP-1 receptor agonists

You can see a list of supported browsers in our Help Center

In turn, the levels of IGF-1 have been shown to be associated with an increased risk of cancer (204, 205)

2018;41(suppl 1):S73-S85

Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and couterregulation during hypoglycemia

Vildagliptin: a review of its use in type 2 diabetes mellitus

This distinction also separates a compounded drug from a generic one: While the latter has an abbreviated FDA-approval process (since the existing brand-name drug has already been shown safe and efficacious), the maker still has to prove to the FDA that their version is equivalent to the OG on both fronts